Sjögren's disease & overlap diseases

Uncovering CD248, MMP28, and SLC16A10 in primary Sjögren's disease: a machine learning-driven SHAP approach for CD4+ T cell-associated biomarker discovery

Clin Exp RheumatolPublished Mechanistic study

Authors' conclusion

Our bioinformatic study identifies CD248, MMP28 and SLC16A10 as candidate biomarkers and therapeutic targets for SjD, with their dysregulation specifically enriched in CD4+ T cell subsets, unveiling a previously underappreciated mechanism in SjD pathogenesis.

Study context

Population
Transcriptomic datasets of sjögren's disease (SjD) patients and healthy controls
Participants
382 samples
Comparison
SjD patients vs healthy controls
  • SjDn = 321
  • Healthy controlsn = 61reference
Outcome
Diagnostic signature (hub) genes identified by machine learning and SHAP
Methodological detailsbioinformatic, 12 machine learning algorithms, SHAP interpretable modelling, external dataset validation, single-cell RNA sequencing (scRNA-seq), molecular docking
  • Bioinformatic
  • 12 machine learning algorithms
  • SHAP interpretable modelling
  • External dataset validation
  • scRNA-seq
  • Molecular docking

Main finding

As reported in the abstract

Hub genes identified (CD248, MMP28, SLC16A10)
Significant differential expression in external datasets
p<0.05
Diagnostic performance in external datasets
AUC >0.7

Further findings

Immune infiltration

Positive correlation of CD248/SLC16A10 with naive CD4+ T cells
P < 0.05
Positive correlation of SLC16A10/MMP28 with memory resting CD4+ T cells
P < 0.05

Single-cell localisation

CD248 predominantly in naive CD4+ T cells; SLC16A10 and MMP28 in both naive and memory CD4+ T cell subsets

Molecular docking

Stable targeting of CD248, MMP28 and SLC16A10 by AZA, LEF, MTX, HCQ, iguratimod, pilocarpine and cevimeline

Original publication

Uncovering CD248, MMP28, and SLC16A10 in primary Sjögren's disease: a machine learning-driven SHAP approach for CD4+ T cell-associated biomarker discovery. Clin Exp Rheumatol. Published 6 June 2025. doi:10.55563/clinexprheumatol/2ffdc4

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.